Wetherby Asset Management Inc Gilead Sciences, Inc. Transaction History

Wetherby Asset Management Inc

$2.08 Billion
Q2 2024

A detailed history of Wetherby Asset Management Inc transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Wetherby Asset Management Inc holds 40,614 shares of GILD stock, worth $3.4 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares

40,614

Previous 54,119 24.95%

Holding current value

$3.4 Million

Previous $3.96 Million 29.72%

% of portfolio

0.13%

Previous 0.19%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$63.15 - $72.88 $852,840 - $984,244	-13,505 Reduced 24.95%	40,614 $2.79 Million
Q1 2024 May 15, 2024	BUY	$71.58 - $87.29 $561,903 - $685,226	7,850 Added 16.97%	54,119 $3.96 Million
Q4 2023 Feb 14, 2024	BUY	$73.27 - $83.09 $62,426 - $70,792	852 Added 1.88%	46,269 $3.75 Million
Q3 2023 Nov 14, 2023	SELL	$73.94 - $80.67 $82,664 - $90,189	-1,118 Reduced 2.4%	45,417 $3.4 Million
Q2 2023 Aug 14, 2023	BUY	$76.01 - $86.7 $100,713 - $114,877	1,325 Added 2.93%	46,535 $3.59 Million
Q1 2023 May 12, 2023	SELL	$77.31 - $88.08 $15,230 - $17,351	-197 Reduced 0.43%	45,210 $3.75 Million
Q4 2022 Feb 14, 2023	SELL	$62.32 - $89.47 $187,209 - $268,767	-3,004 Reduced 6.21%	45,407 $3.9 Million
Q3 2022 Nov 14, 2022	BUY	$59.54 - $68.01 $284,660 - $325,155	4,781 Added 10.96%	48,411 $2.99 Million
Q2 2022 Aug 15, 2022	BUY	$57.72 - $65.01 $271,110 - $305,351	4,697 Added 12.06%	43,630 $2.7 Million
Q1 2022 May 16, 2022	SELL	$57.92 - $72.58 $178,451 - $223,618	-3,081 Reduced 7.33%	38,933 $2.31 Million
Q4 2021 Feb 14, 2022	BUY	$64.88 - $73.64 $29,325 - $33,285	452 Added 1.09%	42,014 $3.05 Million
Q3 2021 Nov 15, 2021	SELL	$67.69 - $73.03 $476,266 - $513,839	-7,036 Reduced 14.48%	41,562 $2.9 Million
Q2 2021 Aug 16, 2021	BUY	$63.47 - $69.35 $954,207 - $1.04 Million	15,034 Added 44.79%	48,598 $3.35 Million
Q1 2021 May 14, 2021	SELL	$60.0 - $68.46 $1.33 Million - $1.51 Million	-22,098 Reduced 39.7%	33,564 $2.17 Million
Q4 2020 Feb 11, 2021	BUY	$56.65 - $64.55 $636,462 - $725,219	11,235 Added 25.29%	55,662 $3.24 Million
Q3 2020 Dec 16, 2020	SELL	$62.1 - $78.08 $987,948 - $1.24 Million	-15,909 Reduced 26.37%	44,427 $2.81 Million
Q3 2020 Nov 13, 2020	BUY	$62.1 - $78.08 $758,862 - $954,137	12,220 Added 25.4%	60,336 $3.81 Million
Q2 2020 Aug 14, 2020	BUY	$72.34 - $84.0 $88,254 - $102,480	1,220 Added 2.6%	48,116 $3.7 Million
Q1 2020 May 06, 2020	BUY	$62.63 - $80.22 $412,606 - $528,489	6,588 Added 16.34%	46,896 $3.51 Million
Q4 2019 Jan 28, 2020	SELL	$61.62 - $67.78 $84,542 - $92,994	-1,372 Reduced 3.29%	40,308 $2.62 Million
Q3 2019 Oct 31, 2019	SELL	$62.51 - $69.0 $123,082 - $135,861	-1,969 Reduced 4.51%	41,680 $2.64 Million
Q2 2019 Jul 25, 2019	BUY	$61.87 - $69.38 $308,483 - $345,928	4,986 Added 12.9%	43,649 $2.95 Million
Q1 2019 May 09, 2019	BUY	$62.53 - $70.05 $44,834 - $50,225	717 Added 1.89%	38,663 $2.51 Million
Q4 2018 Jan 30, 2019	SELL	$60.54 - $79.0 $48,553 - $63,358	-802 Reduced 2.07%	37,946 $2.37 Million
Q3 2018 Nov 07, 2018	SELL	$71.28 - $78.92 $6,771 - $7,497	-95 Reduced 0.24%	38,748 $2.99 Million
Q2 2018 Jul 24, 2018	BUY	$64.88 - $75.68 $13,949 - $16,271	215 Added 0.56%	38,843 $2.75 Million
Q1 2018 May 04, 2018	SELL	$72.84 - $88.8 $39,552 - $48,218	-543 Reduced 1.39%	38,628 $2.91 Million
Q4 2017 Feb 09, 2018	SELL	$71.15 - $83.52 $260,266 - $305,516	-3,658 Reduced 8.54%	39,171 $2.81 Million
Q3 2017 Nov 13, 2017	BUY	$72.11 - $85.47 $3.09 Million - $3.66 Million	42,829	42,829 $3.47 Million

Others Institutions Holding GILD

# of Institutions

1,879

Shares Held

1.02B

Call Options Held

12M

Put Options Held

8.96M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $105B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wetherby Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Wetherby Asset Management Inc with notifications on news.

Account

Wetherby Asset Management Inc Gilead Sciences, Inc. Transaction History